Analyst Ratings For Rocket Pharmaceuticals Inc (NASDAQ:RCKT)
Today, William Blair reiterated its Buy rating on Rocket Pharmaceuticals Inc (NASDAQ:RCKT).
There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Rocket Pharmaceuticals Inc (NASDAQ:RCKT) is Buy with a consensus target price of $28.50 per share, a potential 92.96% upside.
Some recent analyst ratings include
- 11/27/2018-Rocket Pharmaceuticals Inc (NASDAQ:RCKT) had its Buy rating reiterated by William Blair
- 9/13/2018-Rocket Pharmaceuticals Inc (NASDAQ:RCKT) has coverage initiated with a Buy ➝ Buy rating and $30.00 price target
- 5/11/2018-Rocket Pharmaceuticals Inc (NASDAQ:RCKT) had its Buy rating reiterated by Cowen
- 1/30/2018-Rocket Pharmaceuticals Inc (NASDAQ:RCKT) has coverage initiated with a Outperform ➝ Outperform rating and $27.00 price target
- 7/12/2017-Rocket Pharmaceuticals Inc (NASDAQ:RCKT) gets downgraded to Hold by Canaccord Genuity
- 7/11/2017-Rocket Pharmaceuticals Inc (NASDAQ:RCKT) gets downgraded to Neutral by HC Wainwright with a price target of $2.00
- 1/3/2017-Rocket Pharmaceuticals Inc (NASDAQ:RCKT) gets downgraded to Neutral by Piper Jaffray Companies with a price target of $3.00
- On 8/1/2018 Naveen Yalamanchi, Director, sold 637 with an average share price of $22.00 per share and the total transaction amounting to $14,014.00.
- On 1/6/2017 David P. Southwell, Insider, bought 60,000 with an average share price of $1.75 per share and the total transaction amounting to $105,000.00.
- On 5/13/2016 J Martin Carroll, Director, bought 10,000 with an average share price of $9.03 per share and the total transaction amounting to $90,300.00.
- On 2/23/2015 Argeris N Karabelas, Director, bought 603,832 with an average share price of $6.00 per share and the total transaction amounting to $3,622,992.00.
- On 2/23/2015 Park Bioventures Lp Devon, Major Shareholder, bought 814,166 with an average share price of $6.00 per share and the total transaction amounting to $4,884,996.00.
About Rocket Pharmaceuticals Inc (NASDAQ:RCKT)
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, as well as a strategic research collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
Recent Trading Activity for Rocket Pharmaceuticals Inc (NASDAQ:RCKT)
Shares of Rocket Pharmaceuticals Inc closed the previous trading session at 15,07 −1,09 6,75 % with 16.16 shares trading hands.